KINERET® (anakinra) blocks the interleukin-1 (IL-1) receptor to help protect against autoinflammatory events1
IL-1 is a proinflammatory cytokine that plays a key role in autoinflammation.2 Uncontrolled IL-1 activity can lead to chronic and life-threatening systemic inflammation.1,3,4
Kineret [Prescribing Information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ); 2018.
YOU ARE ABOUT TO LEAVE
You are now leaving the SOBI KINERETRX.com website
INDICATIONS
KINERET® (anakinra) is an interleukin-1 receptor antagonist indicated for:
Rheumatoid Arthritis (RA)
Reduction in signs and symptoms and slowing the progression of structural damage in moderately to
severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more
disease-modifying antirheumatic drugs (DMARDs)